RTTNews | Jan 19, 2021 10:11AM EST

10:10 Tuesday, January 19, 2021 (RTTNews.com) - Shares of Aclaris Therapeutics, Inc. (ACRS) are surging over 160% after the clinical-stage biopharmaceutical company announced positive preliminary topline data from mid-stage trial of rheumatoid arthritis treatment.

ACRS is currently trading at $15.56, up $9.68 or 164.63%, on the Nasdaq.

Aclaris announced positive preliminary topline results from a 12-week, Phase 2a clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis.

ATI-450 was developed internally utilizing Aclaris' proprietary KINect drug discovery platform.

Read the original article on RTTNews ( https://www.rttnews.com/3161524/stock-alert-aclaris-therapeutics-surges-160.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved